JY
TXMD icon

Jeff Yass’s TherapeuticsMD TXMD Stock Holding History

Jeff Yass’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Buy
+13,100
New +$27.1K ﹤0.01% 12969
2026
Q1 		– Sell
-24,100
Closed -$39.3K – 14134
2025
Q4 		$39.3K Buy
+24,100
New +$34.8K ﹤0.01% 11826
2025
Q3 		– Sell
-35,800
Closed -$41.5K – 13932
2025
Q2 		$41.5K Buy
+35,800
New +$43.4K ﹤0.01% 12167
2024
Q1 		– Sell
-22,500
Closed -$50.6K – 13362
2023
Q4 		$50.6K Sell
22,500
-2,400
-10% -$5.79K ﹤0.01% 11709
2023
Q3 		$75.2K Sell
24,900
-3,000
-11% -$11.4K ﹤0.01% 11103
2023
Q2 		$115K Buy
27,900
+2,600
+10% +$10.2K ﹤0.01% 10844
2023
Q1 		$94.9K Sell
25,300
-35,300
-58% -$169K ﹤0.01% 11337
2022
Q4 		$339K Sell
60,600
-20,100
-25% -$118K ﹤0.01% 8801
2022
Q3 		$536K Buy
80,700
+5,000
+7% +$40.5K ﹤0.01% 8301
2022
Q2 		$753K Buy
75,700
+74,144
+4,765% +$708K ﹤0.01% 7230
2022
Q1 		$30K Buy
1,556
+898
+136% +$14.1K ﹤0.01% 12505
2021
Q4 		$12K Sell
658
-1,132
-63% -$33.9K ﹤0.01% 12912
2021
Q3 		$66K Sell
1,790
-1,636
-48% -$72.6K ﹤0.01% 12250
2021
Q2 		$204K Sell
3,426
-4,264
-55% -$258K ﹤0.01% 11567
2021
Q1 		$515K Buy
7,690
+6,050
+369% +$474K ﹤0.01% 9395
2020
Q4 		$99K Sell
1,640
-4,492
-73% -$307K ﹤0.01% 10499
2020
Q3 		$484K Buy
6,132
+4,926
+408% +$393K ﹤0.01% 7745
2020
Q2 		$75K Buy
1,206
+578
+92% +$33.7K ﹤0.01% 9633
2020
Q1 		$33K Sell
628
-340
-35% -$33.7K ﹤0.01% 9806
2019
Q4 		$117K Sell
968
-1,452
-60% -$209K ﹤0.01% 9069
2019
Q3 		$439K Sell
2,420
-4,058
-63% -$572K ﹤0.01% 7578
2019
Q2 		$842K Buy
6,478
+3,576
+123% +$641K ﹤0.01% 6080
2019
Q1 		$707K Buy
2,902
+2,096
+260% +$555K ﹤0.01% 5656
2018
Q4 		$154K Sell
806
-1,080
-57% -$263K ﹤0.01% 7964
2018
Q3 		$619K Sell
1,886
-2,290
-55% -$702K ﹤0.01% 6142
2018
Q2 		$1.3M Buy
4,176
+1,654
+66% +$505K ﹤0.01% 4807
2018
Q1 		$614K Buy
2,522
+1,008
+67% +$283K ﹤0.01% 6218
2017
Q4 		$457K Buy
1,514
+30
+2% +$8.35K ﹤0.01% 6813
2017
Q3 		$393K Sell
1,484
-2,526
-63% -$730K ﹤0.01% 6950
2017
Q2 		$1.06M Buy
4,010
+3,288
+455% +$824K ﹤0.01% 5145
2017
Q1 		$260K Sell
722
-3,198
-82% -$990K ﹤0.01% 7589
2016
Q4 		$1.13M Buy
3,920
+686
+21% +$213K ﹤0.01% 5265
2016
Q3 		$1.1M Buy
3,234
+608
+23% +$222K ﹤0.01% 4625
2016
Q2 		$1.12M Sell
2,626
-674
-20% -$278K ﹤0.01% 4650
2016
Q1 		$1.06M Buy
3,300
+248
+8% +$84.6K ﹤0.01% 4982
2015
Q4 		$1.58M Buy
3,052
+1,246
+69% +$460K ﹤0.01% 4523
2015
Q3 		$529K Sell
1,806
-1,188
-40% -$422K ﹤0.01% 7012
2015
Q2 		$1.18M Buy
2,994
+2,250
+302% +$794K ﹤0.01% 5854
2015
Q1 		$225K Buy
+744
New +$182K ﹤0.01% 8466

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jeff Yass's TXMD Position: Q2 2026 in Review

Jeff Yass sold out of TherapeuticsMD (TXMD) in Q2 2026, closing a stake of 21,220 shares — an estimated $43.8K sold.

Jeff Yass first reported a position in TXMD in Q4 2013 and held it in 36 quarters. The position peaked at $8.45M in Q3 2018. 45 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Jeff Yass reported no remaining TherapeuticsMD position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 21,220 TherapeuticsMD shares in Q2 2026, an estimated $43.8K.
  • Jeff Yass first reported a position in TherapeuticsMD in Q4 2013 and held it in 36 quarters.
  • Jeff Yass's TherapeuticsMD position peaked at $8.45M in Q3 2018.
  • 45 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.